Question reference: S6W-03517
- Date lodged: 6 October 2021 Registered interest
-
Current status: Answered by Humza Yousaf on 27 October 2021
Question
To ask the Scottish Government, in light of the comments in its Programme for Government regarding the increased demand for genetic and molecular diagnostic testing linked to new advanced medicines, what steps NHS Scotland is taking to identify as early as possible the required tests for any medicine being considered by the Scottish Medicines Consortium (SMC), in order to prevent any delay between the SMC accepting a medicine and it being available to patients.
Answer
The Scottish Medicines Consortium (SMC) liaises closely with colleagues from National Services Division (NSD) in NHS National Services Scotland (NSS) to share intelligence on emerging new medicines that may require a companion diagnostic test. NSD has commissioning responsibility for the Scottish Genetic Laboratories and is currently conducting a review of NHS Scotland genomics services which includes the Scottish genomic test directory and genomics infrastructure. The review is expected to be complete by the end of March 2022.
The SMC also provides early horizon scanning reports to the Molecular Pathology Evaluation Panel on medicines in clinical development and shares information on the anticipated timelines for these medicines to be granted a marketing authorisation and then be assessed by the SMC. The SMC horizon scanning reports are also supporting ongoing work with NSD, the Scottish Genomics Leadership Group and the Scottish Genetics Laboratory Consortium to understand the laboratory capacity requirements for current and future medicines requiring a companion diagnostic test.